Literature DB >> 28119349

Expression of PTEN and its pseudogene PTENP1, and promoter methylation of PTEN in non-tumourous thymus and thymic tumours.

Atsuko Masunaga1, Mutsuko Omatsu2, Toshiaki Kunimura2, Shugo Uematsu1, Yoshito Kamio3, Akihiko Kitami1, Yohei Miyagi4, Kenzo Hiroshima5, Takashi Suzuki1.   

Abstract

AIMS: Mutation or promoter methylation of the phosphatase tensin homologue deleted on chromosome 10 tumour suppressor gene (PTEN) promotes some cancers. Moreover, PTENP1 (PTEN pseudogene) transcript regulates PTEN expression and is thought to be associated with tumourigenesis in some cancers. Here, we investigated PTEN expression in thymic epithelium and thymic epithelial tumours.
METHODS: Immunohistochemical analysis of PTEN was performed on two non-tumourous thymus (NT) samples, 33 thymomas (three type A, eight type AB, 11 type B1, six type B2, and five type B3), and four thymic carcinomas (TCs). In 16 cases (two NT, three A, five B1, two B2, one B3 and three TC), analyses of mutations, promoter methylation and comparisons of PTEN mRNA and PTENP1 transcripts were undertaken using PCR-direct sequencing, methylation-specific PCR, and reverse-transcription real-time PCR after target cell collection with laser microdissection.
RESULTS: PTEN protein was not immunohistochemically detected in NT epithelium or types B1 or B2 thymoma cells, but was expressed in type A thymoma and carcinoma cells. Neither PTEN mutations nor promoter methylation were detected in any samples. Statistical analysis revealed that PTEN mRNA expression was highest in NT epithelium and lowest in type A thymoma cells. PTENP1 transcript expression did not significantly differ among NT, thymoma and TC samples.
CONCLUSIONS: We speculated that NT epithelium and types B1/B2 thymoma cells have a mechanism of PTEN translation repression and/or acceleration of protein degradation, whereas type A thymoma cells exhibit transcriptional repression of PTEN mRNA and accelerated translation and/or protein accumulation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  CANCER; HISTOPATHOLOGY; IMMUNOCYTOCHEMISTRY; MOLECULAR PATHOLOGY; TUMOUR BIOLOGY

Mesh:

Substances:

Year:  2017        PMID: 28119349     DOI: 10.1136/jclinpath-2016-204220

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  4 in total

1.  [Role of lncRNA PTENP1 in tumorigenesis and progression of bladder cancer and the molecular mechanism].

Authors:  Gan Yu; Zheng-Yue Ou; Qi-Ye Tao; Guo-Yue Wan; Zong-Hao Lu; Bin Lang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-11-20

Review 2.  The functions of tumor suppressor PTEN in innate and adaptive immunity.

Authors:  Lang Chen; Deyin Guo
Journal:  Cell Mol Immunol       Date:  2017-06-26       Impact factor: 11.530

3.  PTENP1 inhibits the growth of esophageal squamous cell carcinoma by regulating SOCS6 expression and correlates with disease prognosis.

Authors:  Tuotuo Gong; Shuyu Zheng; Shan Huang; Shenbo Fu; Xuanwei Zhang; Shupei Pan; Tian Yang; Yuchen Sun; Ya Wang; Beina Hui; Jia Guo; Xiaozhi Zhang
Journal:  Mol Carcinog       Date:  2017-08-21       Impact factor: 4.784

Review 4.  Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations.

Authors:  Iason Psilopatis; Alexandros Pergaris; Kleio Vrettou; Stamatios Theocharis; Constantinos Troungos
Journal:  Int J Mol Sci       Date:  2022-04-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.